[sandbox] K4D COVID-19 Resource Hub

Sort by: Date tagged Date published

97 - 120 of 1176

A Platform to Support the Researchers and Decision-makers Generating and Using Health Economics Research to Tackle COVID-19

https://api.zotero.org/groups/2494380/items/T3JK44SL?format=atom

Zotero / K4D COVID-19 Health Evidence Summaries Group / Top-Level Items 11/27/2020

A Proposed Framework and Timeline of the Spectrum of Disease Due to SARS-CoV-2 InfectionIllness Beyond Acute Infection and Public Health Implications

https://api.zotero.org/groups/2494380/items/YWZT2EEB?format=atom

Zotero / K4D COVID-19 Health Evidence Summaries Group / Top-Level Items 11/27/2020

A look inside laboratories responding to COVID-19

https://api.zotero.org/groups/2494380/items/P2Y8AN29?format=atom

Zotero / K4D COVID-19 Health Evidence Summaries Group / Top-Level Items 11/27/2020

India’s syndemic of tuberculosis and COVID-19

https://api.zotero.org/groups/2494380/items/ED7W9T7W?format=atom

Zotero / K4D COVID-19 Health Evidence Summaries Group / Top-Level Items 11/27/2020

Therapeutics and COVID-19: living guideline

https://api.zotero.org/groups/2494380/items/I9SQ57KE?format=atom

Zotero / K4D COVID-19 Health Evidence Summaries Group / Top-Level Items 11/27/2020

Considerations for implementing and adjusting public health and social measures in the context of COVID-19

https://api.zotero.org/groups/2494380/items/B6I5TWFT?format=atom

Zotero / K4D COVID-19 Health Evidence Summaries Group / Top-Level Items 11/27/2020

More money for health services: What is the role of PFM in the “new normal”? 📅 (webinar, Dec. 3)

https://api.zotero.org/groups/2494380/items/6AAW3M4F?format=atom

Zotero / K4D COVID-19 Health Evidence Summaries Group / Top-Level Items 11/27/2020

COVID-19, Supply Chain Resilience and Global Trade | Center For Global Development

https://api.zotero.org/groups/2494380/items/K9R7I4FX?format=atom

Zotero / K4D COVID-19 Health Evidence Summaries Group / Top-Level Items 11/27/2020

Seroprevalence of anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors

https://api.zotero.org/groups/2494380/items/35LT24YD?format=atom

Zotero / K4D COVID-19 Health Evidence Summaries Group / Top-Level Items 11/25/2020

Cost-effectiveness of public health strategies for COVID-19 epidemic control in South Africa: a microsimulation modelling study

https://api.zotero.org/groups/2494380/items/RSWL2RV2?format=atom

Zotero / K4D COVID-19 Health Evidence Summaries Group / Top-Level Items 11/25/2020

Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host

https://api.zotero.org/groups/2494380/items/JLV2JTU4?format=atom

Zotero / K4D COVID-19 Health Evidence Summaries Group / Top-Level Items 11/25/2020

Combating the COVID-19 pandemic in a resource-constrained setting: insights from initial response in India

https://api.zotero.org/groups/2494380/items/MSBSRIB7?format=atom

Zotero / K4D COVID-19 Health Evidence Summaries Group / Top-Level Items 11/25/2020

Accuracy of UK Rapid Test Consortium (UK-RTC) “AbC-19 Rapid Test” for detection of previous SARS-CoV-2 infection in key workers: test accuracy study

https://api.zotero.org/groups/2494380/items/IR2Q5EW9?format=atom

Zotero / K4D COVID-19 Health Evidence Summaries Group / Top-Level Items 11/25/2020

Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial

https://api.zotero.org/groups/2494380/items/N5VYNNUJ?format=atom

Zotero / K4D COVID-19 Health Evidence Summaries Group / Top-Level Items 11/25/2020

Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19A Randomized Clinical Trial

https://api.zotero.org/groups/2494380/items/QFPSCE64?format=atom

Zotero / K4D COVID-19 Health Evidence Summaries Group / Top-Level Items 11/25/2020

Moderna Announces Longer Shelf Life for its COVID-19 Vaccine Candidate at Refrigerated Temperatures | Moderna, Inc.

https://api.zotero.org/groups/2494380/items/GW87ENBD?format=atom

Zotero / K4D COVID-19 Health Evidence Summaries Group / Top-Level Items 11/25/2020

Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study | Moderna, Inc.

https://api.zotero.org/groups/2494380/items/7S5B5M65?format=atom

Zotero / K4D COVID-19 Health Evidence Summaries Group / Top-Level Items 11/25/2020

Teenage pregnancies rise in parts of Kenya as lockdown shuts schools

https://api.zotero.org/groups/2494380/items/CNZ5BDM3?format=atom

Zotero / K4D COVID-19 Health Evidence Summaries Group / Top-Level Items 11/25/2020

Hydroxychloroquine and COVID-19: a tale of populism and obscurantism

https://api.zotero.org/groups/2494380/items/SM6P37IW?format=atom

Zotero / K4D COVID-19 Health Evidence Summaries Group / Top-Level Items 11/25/2020

Provision of holistic care after severe COVID-19 pneumonia: anticipating clinical need and managing resources

https://api.zotero.org/groups/2494380/items/W9JI4P6K?format=atom

Zotero / K4D COVID-19 Health Evidence Summaries Group / Top-Level Items 11/25/2020

COVID mink analysis shows mutations are not dangerous — yet

https://api.zotero.org/groups/2494380/items/DUWXAJJB?format=atom

Zotero / K4D COVID-19 Health Evidence Summaries Group / Top-Level Items 11/25/2020

Nebulised interferon beta-1a for patients with COVID-19

https://api.zotero.org/groups/2494380/items/QFA8C6RL?format=atom

Zotero / K4D COVID-19 Health Evidence Summaries Group / Top-Level Items 11/25/2020

Beyond the Rhetoric of Equity: Will the Frontline Healthcare Workers Who Serve the Poor Be Prioritized for the COVID Vaccine?

https://api.zotero.org/groups/2494380/items/8NQJJA9L?format=atom

Zotero / K4D COVID-19 Health Evidence Summaries Group / Top-Level Items 11/25/2020

Strong health care systems are key to deliver COVID-19 vaccines

https://api.zotero.org/groups/2494380/items/2K5KWRPU?format=atom

Zotero / K4D COVID-19 Health Evidence Summaries Group / Top-Level Items 11/25/2020

97 - 120 of 1176